Fidelity Investments
PACB icon

Fidelity Investments’s Pacific Biosciences PACB Stock Holding History

Fidelity Investments’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.6K Sell
25,342
-11,641
-31% -$16.9K ﹤0.01% 4375
2026
Q1 		$48.8K Buy
36,983
+7,128
+24% +$12.8K ﹤0.01% 4139
2025
Q4 		$55.8K Buy
29,855
+11,279
+61% +$21.7K ﹤0.01% 4053
2025
Q3 		$23.8K Sell
18,576
-547
-3% -$741 ﹤0.01% 4287
2025
Q2 		$23.7K Buy
19,123
+10,377
+119% +$12K ﹤0.01% 4231
2025
Q1 		$10.3K Sell
8,746
-13,907
-61% -$21.3K ﹤0.01% 4483
2024
Q4 		$41.5K Sell
22,653
-385,498
-94% -$752K ﹤0.01% 3931
2024
Q3 		$694K Buy
408,151
+353,092
+641% +$580K ﹤0.01% 2734
2024
Q2 		$75.4K Sell
55,059
-797,848
-94% -$1.61M ﹤0.01% 3425
2024
Q1 		$3.2M Sell
852,907
-2,872,147
-77% -$16.8M ﹤0.01% 2193
2023
Q4 		$36.5M Sell
3,725,054
-897,866
-19% -$7.34M ﹤0.01% 1411
2023
Q3 		$38.6M Buy
4,622,920
+892,145
+24% +$10.2M ﹤0.01% 1339
2023
Q2 		$49.6M Sell
3,730,775
-637,392
-15% -$7.75M ﹤0.01% 1278
2023
Q1 		$50.6M Buy
4,368,167
+4,217,484
+2,799% +$41.9M ﹤0.01% 1261
2022
Q4 		$1.23M Sell
150,683
-37,617
-20% -$324K ﹤0.01% 2497
2022
Q3 		$1.09M Sell
188,300
-1,032,423
-85% -$5.92M ﹤0.01% 2580
2022
Q2 		$5.39M Sell
1,220,723
-258,710
-17% -$1.57M ﹤0.01% 2216
2022
Q1 		$13.5M Sell
1,479,433
-312,858
-17% -$3.6M ﹤0.01% 1993
2021
Q4 		$36.7M Buy
1,792,291
+1,528,880
+580% +$36.9M ﹤0.01% 1554
2021
Q3 		$6.73M Buy
263,411
+73
+0% +$2.16K ﹤0.01% 2270
2021
Q2 		$9.21M Sell
263,338
-2,712,824
-91% -$78.9M ﹤0.01% 2138
2021
Q1 		$99.1M Buy
2,976,162
+2,975,982
+1,653,323% +$104M 0.01% 1071
2020
Q4 		$5K Buy
180
+129
+253% +$2.19K ﹤0.01% 3450
2020
Q3 		$1K Buy
+51
New +$294 ﹤0.01% 3591
2015
Q1 		– Sell
-60,000
Closed -$470K – 2781
2014
Q4 		$470K Buy
+60,000
New +$384K ﹤0.01% 2652

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments's PACB Position: Q2 2026 in Review

Fidelity Investments reduced its Pacific Biosciences (PACB) stake by 31% in Q2 2026, selling an estimated $16.9K and leaving 25,342 shares worth $42.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4375.

Fidelity Investments first reported a position in PACB in Q4 2014 and has held it in 25 quarters since. The position peaked at $99.1M in Q1 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Fidelity Investments held 25,342 shares of Pacific Biosciences worth $42.6K as of Q2 2026.
  • Fidelity Investments sold 11,641 Pacific Biosciences shares in Q2 2026, an estimated $16.9K.
  • Pacific Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4375 holding.
  • Fidelity Investments first reported a position in Pacific Biosciences in Q4 2014 and has held it in 25 quarters since.
  • Fidelity Investments's Pacific Biosciences position peaked at $99.1M in Q1 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.